Curated, plain-language updates on pharmaceuticals — each summarized and linked to its original source.
9 items
The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemi
Read moreFirst-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction in patients with acute MI undergoing PCI, with more than 80% reaching the guideline recommended target of LDL-C less than 55 mg/dL at one year, said researchers presenting findings from the AMUNDSEN trial at ESC Congress 2026. However, no clinical benefit was detected during the first year of follow-up.
Read moreAmong community-dwelling older adults, treatment with atorvastatin demonstrated a 30% relative reduction in major cardiovascular events over roughly six years compared with placebo but did not result in longer disability-free survival, based on findings from the STAREE trial presented at ESC Congress 2026 and simultaneously published in NEJM.
Read moreIn this interview, Nanette Kass Wenger MD, MACC and Nicholas Marston, MD discuss the VESALIUS-CV Trial.
Read moreDear EditorThe 2025 focus update for dyslipidaemia of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) highlights a more personalised strategy for LDL-cholesterol...
Read moreGLP-1RA (glucagon-like peptide-1 receptor agonist) medications, which are prescribed to treat Type 2 diabetes and to help with weight loss, were found to reduce the number of deaths, amputations and hospitalizations among people
Read moreearly version to give early visibility of the article.
Read moreThe NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome has emerged as a critical mediator in cardiovascular diseases, connecting cholesterol crystals and metabolic danger signals to atherogenic inflammation, myocardial injury, and adverse remodeling. Using direct inhibitors that bind to NLRP3 has advantages over indirect strategies. These advantages include retaining the function of other inflammatory body sensors and the potential for oral treatment.
Read moreBackground In diabetic kidney disease (DKD), dyslipidemia accelerates renal decline and heart failure risk, making Cardio-Renal-Metabolic (CRM) risk reduction critical. The bidirectional relationship between cardiac and renal dysfunction further highlights the necessity of lipid-lowering therapy as a common intervention pathway; however, its comparative efficacy remains unclear. Objective To compare the Cardio-Renal-Metabolic (CRM) outcomes of various lipid-lowering agents. Methods We searched…
Read more